Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Gross Profit: 2016-2025

Historic Gross Profit for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to $351,000.

  • Seres Therapeutics' Gross Profit was N/A to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $107,000, marking a year-over-year change of. This contributed to the annual value of $126.3 million for FY2023, which is 1672.24% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Gross Profit is $351,000, which was up 156.80% from -$618,000 recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Gross Profit ranged from a high of $126.7 million in Q3 2021 and a low of -$618,000 during Q1 2024.
  • Moreover, its 3-year median value for Gross Profit was $330,500 (2023), whereas its average is $21.2 million.
  • Per our database at Business Quant, Seres Therapeutics' Gross Profit soared by 10,300.74% in 2023 and then slumped by 218.39% in 2024.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Gross Profit stood at $7.2 million in 2021, then tumbled by 86.50% to $975,000 in 2022, then tumbled by 93.44% to $64,000 in 2023, then crashed by 218.39% to -$618,000 in 2024, then reached $351,000 in 2025.
  • Its last three reported values are $351,000 in Q3 2025, -$618,000 for Q1 2024, and $64,000 during Q4 2023.